GPS Rebrands as “Thredd” to Reflect Its Unique Position as the Go to Payments Partner of Innovators Worldwide
27.4.2023 12:00:00 EEST | Business Wire | Press release
Global Processing Services, a next generation global payments platform behind the leading fintechs, digital banks, and embedded finance providers across the UK, Europe, Asia, Middle East and North America, has today rebranded as “Thredd,” to reflect the company’s pivotal role in weaving together the different ‘threads’ of the global payments ecosystem to fuel the growth of electronic payments.
With a new leadership team comprising of industry veterans coupled with the backing of future-focused investors, this rebranding signals the next phase of customer partnership and product innovation to bring the aspirations of innovative payments visionaries to life.
Thredd is known for its customer-centred approach to enable payments innovators to launch new card programmes quickly, easily, and cost effectively. Thredd has created a unique niche as a hands-on, modern processor providing reliable digital payment processing capabilities, including real-time, bespoke card management tools, reporting, and world-class fraud prevention technology.
Certified by both Visa and Mastercard, and supporting debit, prepaid and credit programs, Thredd has enabled modern payments issuer processing since 2007 and has earned a reputation as a trusted, reliable and scalable platform.
Today, Thredd’s next-gen platform processes billions of transactions annually and powers over 100 customers across 44 countries and a broad range of use cases. Thredd is the processing partner of choice for an array of verticals, including digital banking, Buy Now Pay Later (BNPL), Travel, and Banking-as-a-Service (BaaS).
One of Thredd’s fastest growing customers today is “financial super app” Curve which allows customers to combine most debit, credit, and loyalty cards into one platform and a linked smart card for payments. Thredd has provided the issuer processing firepower for Curve’s platform since it was founded in 2016, supporting the innovative fintech as it has scaled to over 4 million customers, diversified its products, and expanded into international markets.
“Our rebranding to Thredd marks a new era for our company as we begin the next phase of our growth. We’ve spent the last six months building our management team with industry veterans to expand our platform capabilities and deepen our commitment to serving the needs of the most innovative fintechs and banks in the world, said Kevin Schultz, Chief Executive Officer of Thredd.
“Our new brand reflects our renewed focus on enabling our clients to create a more interconnected, accessible, and seamless payments ecosystem. With our experienced team and owners, we’re confident in our vision to bring our partnership approach to modern payments processing to innovators worldwide.”
Explaining why the name Thredd was chosen, Betsy Samuel, Chief Marketing Officer of Thredd, said: “Our clients, partners and team members have told us that we are the ultimate connector, bringing true partnership to the world of payments. This is our DNA, and we wanted a new name to reflect this special identity as well as our expanding position as a pivotal modern payments processor at the heart of the constantly evolving digital economy. We are proud to relaunch with a name which reflects our unique role and reputation as a critical ‘thread’ of the fabric in the ecosystem.”
Thredd is backed by an experienced private equity consortium with specialist experience in scaling payments-related tech businesses, including Advent International, Viking Global Investors, Temasek, and MissionOG; with institutional investors including Mastercard and Visa.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230427005429/en/
Contact information
Media:
Louisa Bartoszek
Head of Communications
louisa.bartoszek@thredd.com
Cognito Media
thredd@cognitomedia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom